加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$50.73
−US$1.72 · -3.28%
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
常规交易时段
US$50.73
−US$1.72 · -3.28%
盘中时间采用ET。市场数据可能有所延迟。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日内区间
当前US$50.73
52周区间
当前US$50.73
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
13
估值过高
情绪
63
看涨
风险
57
风险偏高
动量
62
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
日内区间
当前US$50.73
52周区间
当前US$50.73
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$60.20
上涨空间 18.67%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2791.36万0.00%2.3万亿 USD0.03%US$381.08-0.13%
iShares Russell 2000 ETFIWM2543.25万0.03%787.4亿 USD0.19%US$276.68-0.44%
Vanguard Extended Market ETFVXF1087.54万0.01%954亿 USD0.05%US$232.53-0.42%
iShares Russell 2000 Growth ETFIWO910.51万0.07%139.17亿 USD0.24%US$351.77-0.55%
Schwab U.S. Small-Cap ETFSCHA557.36万0.03%217.13亿 USD0.03%US$32.525-0.41%
Vanguard Russell 2000 ETFVTWO536.95万0.03%180亿 USD0.06%US$111.75-0.47%
iShares U.S. Medical Devices ETFIHI518.17万0.14%35.74亿 USD0.37%US$52.10-1.31%
Invesco Dorsey Wright Healthcare Momentum ETFPTH333.32万1.16%2.87亿 USD0.74%US$57.865-0.88%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares U.S. Medical Devices ETFIHIInvesco Dorsey Wright Healthcare Momentum ETFPTHAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
